A Window for Enhanced Oral Delivery of Therapeutics Via Lipid Nanoparticles

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Mar 13

PMID 38476206

Authors

Hilda Amekyeh

Rayan Sabra

Nashiru Billa

Affiliations

Soon will be listed here.

Abstract

Oral administration of dosage forms is convenient and beneficial in several respects. Lipid nanoparticulate dosage forms have emerged as a useful carrier system in deploying low solubility drugs systemically, particularly class II, III, and IV drugs of the Biopharmaceutics Classification System. Like other nanoparticulate delivery systems, their low size-to-volume ratio facilitates uptake by phagocytosis. Lipid nanoparticles also provide scope for high drug loading and extended-release capability, ensuring diminished systemic side effects and improved pharmacokinetics. However, rapid gastrointestinal (GI) clearance of particulate delivery systems impedes efficient uptake across the mucosa. Mucoadhesion of dosage forms to the GI mucosa results in longer transit times due to interactions between the former and mucus. Delayed transit times facilitate transfer of the dosage form across the mucosa. In this regard, a balance between mucoadhesion and mucopenetration guarantees optimal systemic transfer. Furthermore, the interplay between GI anatomy and physiology is key to ensuring efficient systemic uptake. This review captures salient anatomical and physiological features of the GI tract and how these can be exploited for maximal systemic delivery of lipid nanoparticles. Materials used to impart mucoadhesion and examples of successful mucoadhesive lipid nanoformulations are highlighted in this review.

References

Yeh T, Hsu L, Tseng M, Lee P, Sonjae K, Ho Y . Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials. 2011; 32(26):6164-73. DOI: 10.1016/j.biomaterials.2011.03.056. View

Wibel R, Braun D, Hammerle L, Jorgensen A, Knoll P, Salvenmoser W . In Vitro Investigation of Thiolated Chitosan Derivatives as Mucoadhesive Coating Materials for Solid Lipid Nanoparticles. Biomacromolecules. 2021; 22(9):3980-3991. PMC: 8441978. DOI: 10.1021/acs.biomac.1c00776. View

Hasanein Asfour M, Salama A, Mohsen A . Fabrication of All-Trans Retinoic Acid loaded Chitosan/Tripolyphosphate Lipid Hybrid Nanoparticles as a Novel Oral Delivery Approach for Management of Diabetic Nephropathy in Rats. J Pharm Sci. 2021; 110(9):3208-3220. DOI: 10.1016/j.xphs.2021.05.007. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A . Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015; 495(1):439-446. DOI: 10.1016/j.ijpharm.2015.09.014. View

Florek J, Caillard R, Kleitz F . Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers. Nanoscale. 2017; 9(40):15252-15277. DOI: 10.1039/c7nr05762h. View

Evans D, Pye G, Bramley R, Clark A, Dyson T, Hardcastle J . Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988; 29(8):1035-41. PMC: 1433896. DOI: 10.1136/gut.29.8.1035. View

Basile M, Neri M, Carriero A, Casciardi S, Comani S, Del Gratta C . Measurement of segmental transit through the gut in man. A novel approach by the biomagnetic method. Dig Dis Sci. 1992; 37(10):1537-43. DOI: 10.1007/BF01296499. View

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

10.

Wang G, Wang J, Wu W, To S, Zhao H, Wang J . Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015; 12(9):1475-99. DOI: 10.1517/17425247.2015.1021681. View

11.

Strugala V, Allen A, Dettmar P, Pearson J . Colonic mucin: methods of measuring mucus thickness. Proc Nutr Soc. 2003; 62(1):237-43. DOI: 10.1079/pns2002205. View

12.

Shi L, Xie H, Lu J, Cao Y, Liu J, Zhang X . Positively Charged Surface-Modified Solid Lipid Nanoparticles Promote the Intestinal Transport of Docetaxel through Multifunctional Mechanisms in Rats. Mol Pharm. 2016; 13(8):2667-76. DOI: 10.1021/acs.molpharmaceut.6b00226. View

13.

Soybel D . Anatomy and physiology of the stomach. Surg Clin North Am. 2005; 85(5):875-94, v. DOI: 10.1016/j.suc.2005.05.009. View

14.

Yu Z, Fan W, Wang L, Qi J, Lu Y, Wu W . Effect of Surface Charges on Oral Absorption of Intact Solid Lipid Nanoparticles. Mol Pharm. 2019; 16(12):5013-5024. DOI: 10.1021/acs.molpharmaceut.9b00861. View

15.

Chanburee S, Tiyaboonchai W . Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin. Drug Dev Ind Pharm. 2016; 43(3):432-440. DOI: 10.1080/03639045.2016.1257020. View

16.

Menzel C, Bernkop-Schnurch A . Enzyme decorated drug carriers: Targeted swords to cleave and overcome the mucus barrier. Adv Drug Deliv Rev. 2017; 124:164-174. DOI: 10.1016/j.addr.2017.10.004. View

17.

Jannin V, Lemagnen G, Gueroult P, Larrouture D, Tuleu C . Rectal route in the 21st Century to treat children. Adv Drug Deliv Rev. 2014; 73:34-49. DOI: 10.1016/j.addr.2014.05.012. View

18.

Piazzini V, Cinci L, DAmbrosio M, Luceri C, Bilia A, Bergonzi M . Solid Lipid Nanoparticles and Chitosan-coated Solid Lipid Nanoparticles as Promising Tool for Silybin Delivery: Formulation, Characterization, and In vitro Evaluation. Curr Drug Deliv. 2018; 16(2):142-152. DOI: 10.2174/1567201815666181008153602. View

19.

Amekyeh H, Billa N, Yuen K, Chin S . A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats. AAPS PharmSciTech. 2015; 16(4):871-7. PMC: 4508287. DOI: 10.1208/s12249-014-0279-4. View

20.

Billa N, Yuen K, Khader M, Omar A . Gamma-scintigraphic study of the gastrointestinal transit and in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices. Int J Pharm. 2000; 201(1):109-20. DOI: 10.1016/s0378-5173(00)00399-9. View